SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus upcoming oncology milestones are driving attention, particularly the completed IMPACT pancreatic-cancer trial enrollment and expected data, alongside further REGAIN glioblastoma updates. Traders are broadly optimistic about the expanding pipeline, while some emphasize that larger datasets are still needed to validate the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity and warrant offering, alongside its Elisity acquisition, has put dilution and capital allocation at the center of the discussion as shares have sold off. Bulls see the financing and acquisitions as building a broader quantum platform, while critics question shareholder costs and execution; a Google quantum breakthrough has also lifted sector optimism, though traders disagree on whether that can overcome IONQ-specific concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are watching a governance vote that could make NEAR less inflationary, with some viewing the tokenomics change as a potential catalyst. Sentiment is split: dip-buyers are accumulating, while cautious traders point to Bitcoin-linked weakness and liquidation risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded Global-E and raised Annexon's target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.read more...

Annexon (ANNX) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Annexon (ANNX) to Release Earnings on Monday

Annexon (NASDAQ:ANNX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Moderate Buy" by Brokerages

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat.com reports. One investment...

Annexon CEO Touts Win Year 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a win...

Annexon (NASDAQ:ANNX) Trading 8.5% Higher Following Insider Buying Activity

Annexon (NASDAQ:ANNX) Shares Up 8.5% on Insider Buying Activity...

William Carson Buys 8,000 Shares of Annexon (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson bought 8,000 shares of the firm's stock in a transaction dated Friday, April 10th. The stock was purchased at an average cost of $6.20 per share, with a total value of $49,600.00. Following the transaction, the director directly...

Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 8,000 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson acquired 8,000 shares of the firm's stock in a transaction that occurred on Friday, April 10th. The stock was acquired at an average cost of $6.20 per share, with a total value of $49,600.00. Following the completion of the...

Annexon (NASDAQ:ANNX)  Shares Down 6.1%   - Here's Why

Annexon (NASDAQ:ANNX) Stock Price Down 6.1% - Should You Sell...

HC Wainwright Issues Positive Estimate for Annexon Earnings

Annexon, Inc. (NASDAQ:ANNX - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 earnings estimates for shares of Annexon in a research report issued on Thursday, April 2nd. HC Wainwright...

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Annexon Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.05
Prev Close	$4.01
Open	$4.00
Dividend Yield	0.00%
50-Day Moving Average	$4.20
Beta	1.38
Avg. Volume	3.26M
PE Ratio	-3.53

52-Week High	$7.18
52-Week Low	$2.54
Market Capitalization	$767.8M
EPS (Annual)	-$1.34
Price to Book	3.80
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANNX Fundamentals